Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000

Baudax Bio, a pharmaceutical company focused on innovative products for acute care, has announced additional positive results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery. The analysis of electromyography (EMG) confirmed earlier conclusions that BX1000 at the highest dose compares favorably to rocuronium. The trial was a rando..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 8.
  • textsms

Study: Biosimilars ‘Fulfilling Their Promise’ of Lowering Biologic Prices

A new study from the University of Southern California’s Leonard D. Schaeffer Center for Health Policy & Economics has found that biosimilars are fulfilling their promise to reduce biologic drug prices. The study focused on Genentech’s breast cancer treatment Herceptin and its five biosimilar competitors that entered the US market starting in 2019. When Herceptin's first biosimilar competitor, K..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 8.
  • textsms